Revisiting amoxicillin prophylaxis for infective endocarditis: a pharmacokinetic and cost-effectiveness analysis
This study suggests that while antibiotic prophylaxis for infective endocarditis remains cost-effective for high-risk patients, the current high-dose amoxicillin regimen is pharmacokinetically inefficient and significantly more expensive than lower-dose divided regimens, which achieve comparable systemic exposure at a fraction of the cost.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the world of medicine, preventing a serious heart infection called infective endocarditis often involves giving patients antibiotics before certain dental procedures. This practice, known as prophylaxis, has been a subject of intense debate for decades. The core question has always been whether the benefit of stopping bacteria from entering the bloodstream during dental work outweighs the risks of using antibiotics unnecessarily. Recently, guidelines in the United Kingdom have shifted back toward recommending these preventive doses for patients at the highest risk. However, while doctors and policymakers have argued fiercely over who should receive the medication, very little attention has been paid to how the medication is given. The standard approach involves a single, massive dose of amoxicillin, a common antibiotic, taken just before the appointment. This method assumes that a huge spike in drug concentration is the best way to protect the heart, but it ignores a fundamental rule of how this specific drug works inside the human body.
A new study from researchers at Newcastle University and Newcastle Dental Hospital suggests that the current way of prescribing this antibiotic might be inefficient and unnecessarily expensive. The team looked at the biology of the drug, the cost of different pill formats, and the economics of preventing heart infections. They found that the body struggles to absorb very large doses of amoxicillin all at once. Instead of a single giant dose, the researchers proposed that smaller doses taken repeatedly might actually keep the drug levels high enough to be effective for a longer period. More importantly, they discovered that the way the drug is packaged and sold in the United Kingdom has created a massive price gap. The standard high-dose option is sold in a format that forces patients to pay for far more medication than they actually need, making a potentially life-saving prevention strategy much more costly than it needs to be.
The researchers began by examining how amoxicillin behaves once it is swallowed. Amoxicillin is a type of antibiotic that works best when its concentration in the blood stays above a certain level for a sustained amount of time, rather than just reaching a very high peak for a brief moment. This is a well-known principle in pharmacology, but the current dental guidelines recommend a single dose of three grams, which is a very large amount. When the scientists reviewed decades of published data, they found that the human body does not absorb this drug in a straight line. As the dose gets larger, the percentage of the drug that actually enters the bloodstream drops significantly. In fact, when a person takes a three-gram dose, the body absorbs less than half of it. The rest is simply excreted without providing any extra protection. This means that doubling the dose does not double the protection; it mostly just doubles the waste.
To test if a different approach could work better, the team used computer simulations to model what happens in the blood after taking the drug. They compared the standard single three-gram dose against a strategy of taking smaller 500-milligram doses every six hours. The results showed that the repeated smaller doses kept the drug levels in the blood above the necessary safety threshold for a longer duration. Even though the total amount of drug used in the repeated strategy was much lower, the protection it offered was comparable to the massive single dose. This suggests that the current high-dose regimen is pharmacokinetically inefficient, relying on a peak that the body cannot fully utilize, rather than a steady presence that the drug is designed to provide.
The economic side of the study revealed an even more striking problem. The researchers analyzed the prices of amoxicillin as listed in the official NHS Drug Tariff. They found that the standard three-gram dose is sold in sachets that come in packs of two, even though a patient only needs one for a single procedure. Because the price is set for the entire pack, a single dose effectively costs the health system the price of two. In 2025, a single three-gram sachet cost roughly twenty-two pounds, but because it must be dispensed as a pack of two, the cost for one prophylactic course jumped to over forty-five pounds. In contrast, the same amount of drug, if given as six standard 500-milligram capsules, would cost less than half a pound. This created a situation where the standard method was nearly one hundred times more expensive than an alternative that used the exact same active ingredient.
When the researchers combined the biological data with the cost data, they built a model to see if the prevention strategy was still worth the money. For patients at the highest risk of heart infection, the study found that prophylaxis remained a cost-effective measure under almost every scenario. If the drug was given as capsules, it actually saved the health system money compared to doing nothing, because preventing a heart infection is far cheaper than treating one. Even when using the expensive sachet format, the treatment remained cost-effective, meaning the health benefits justified the cost, though it no longer saved money overall. However, for patients at a moderate risk, the choice of format became critical. With the expensive sachet, the treatment was not considered cost-effective for this group, but with the cheap capsule version, it was. This means that for many patients, the decision to use antibiotics depends entirely on which pill format is chosen, not on the medical need itself.
The study concludes that while the debate over whether to give antibiotics has largely settled in favor of treating high-risk patients, the debate over how to give them is far from over. The current reliance on a single, massive dose appears to be a relic of older thinking that prioritizes a quick spike in drug levels over the steady presence the drug actually needs. The researchers suggest that switching to a divided-dose regimen using standard capsules could achieve the same biological protection while cutting costs dramatically. They emphasize that this change does not require new clinical trials to prove it works, as the biological and economic logic is already clear. However, they also note that future studies are needed to confirm that these theoretical advantages translate into better real-world outcomes for patients. For now, the findings offer a clear path to making a controversial medical practice more efficient, effective, and affordable.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.